Industry Strength Score
11/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
DEXCOM INC (DC4.DE) Stock Price & Overview
FRA:DC4 • US2521311074
Current stock price
49.7 EUR
+0.5 (+1.02%)
Last:
The current stock price of DC4.DE is 49.7 EUR. Today DC4.DE is up by 1.02%. In the past month the price decreased by -14.09%. In the past year, price decreased by -30.18%.
DC4.DE Key Statistics
52-Week Range47 - 77.99
Current DC4.DE stock price positioned within its 52-week range.
1-Month Range48.8 - 58.39
Current DC4.DE stock price positioned within its 1-month range.
- Market Cap
- 19.128B
- P/E
- 31.26
- Fwd P/E
- 22.87
- EPS (TTM)
- 1.59
- Dividend Yield
- N/A
DC4.DE Stock Performance
Today
+1.02%
1 Week
-9.31%
1 Month
-14.09%
3 Months
-19.44%
Longer-term
6 Months -0.09%
1 Year -30.18%
2 Years -58.53%
3 Years -53.94%
5 Years -42.74%
10 Years N/A
DC4.DE Stock Chart
DC4.DE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to DC4.DE. When comparing the yearly performance of all stocks, DC4.DE is a bad performer in the overall market: 93.17% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
DC4.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to DC4.DE. DC4.DE gets an excellent profitability rating and is at the same time showing great financial health properties.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
DC4.DE Earnings
On February 12, 2026 DC4.DE reported an EPS of 0.45 and a revenue of 1.26B. The company missed EPS expectations (-32.12% surprise) and missed revenue expectations (-0.9% surprise).
Next Earnings DateApr 30, 2026
Last Earnings DateFeb 12, 2026
PeriodQ4 / 2025
EPS Reported$0.45
Revenue Reported1.26B
EPS Surprise -32.12%
Revenue Surprise -0.90%
DC4.DE Forecast & Estimates
37 analysts have analysed DC4.DE and the average price target is 76.2 EUR. This implies a price increase of 53.31% is expected in the next year compared to the current price of 49.7.
For the next year, analysts expect an EPS growth of 36.73% and a revenue growth 12.62% for DC4.DE
Analysts
Analysts84.86
Price Target76.2 (53.32%)
EPS Next Y36.73%
Revenue Next Year12.62%
DC4.DE Financial Highlights
Over the last trailing twelve months DC4.DE reported a non-GAAP Earnings per Share(EPS) of 1.59. The EPS increased by 12.73% compared to the year before.
Income Statements
Revenue(TTM)4.66B
Net Income(TTM)836.30M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.94% | ||
| ROA | 13.19% | ||
| ROE | 30.46% | ||
| Debt/Equity | 0.47 |
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%13.12%
EPS 1Y (TTM)12.73%
Revenue 1Y (TTM)15.6%
DC4.DE Ownership
Ownership
Inst Owners101.29%
Shares384.86M
Float382.94M
Ins Owners0.25%
Short Float %N/A
Short RatioN/A
DC4.DE Industry Overview
DC4.DE operates in the Health Care Equipment sub-industry within the Health Care sector. This group contains 127 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
60/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
22%
Outperformed 22% of sub-industries
3 Month Rank
14%
Outperformed 14% of sub-industries
6 Month Rank
11%
Outperformed 11% of sub-industries
Industry Fundamentals & Breadth
- Members
- 127
- New Highs
- 2.4%
- New Lows
- 14.2%
- Average ROE
- 17.2%
- Average Profit Margin
- 20.3%
- Average Operating Margin
- 22.5%
- Average P/E
- 28.1
- Average Fwd P/E
- 27.3
- Average Debt/Equity
- 0.5
DC4.DE Competitors/Peers
The largest stocks on the EU markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 2M6 | MEDTRONIC PLC | 13.05 | 87.766B | ||
| SHL | SIEMENS HEALTHINEERS AG | 13.17 | 39.345B | ||
| PHIA | KONINKLIJKE PHILIPS NV | 14.77 | 21.56B | ||
| PHI1 | KONINKLIJKE PHILIPS NV | 14.76 | 21.55B | ||
| BIM | BIOMERIEUX | 14.88 | 8.486B | ||
| OBCK | OTTOBOCK SE & CO KGAA | 19.4 | 3.731B | ||
| DIA | DIASORIN SPA | 14.33 | 3.246B | ||
| AFX | CARL ZEISS MEDITEC AG - BR | 14.14 | 2.368B | ||
| DRW3 | DRAEGERWERK AG - PREF | 11.01 | 1.679B | ||
| DRW8 | DRAEGERWERK AG | 8.61 | 1.313B | ||
| ELN | EL.EN. SPA | 17.32 | 1.052B | ||
| EUZ | ECKERT & ZIEGLER SE | 18.95 | 969.315M | ||
| GVS | GVS SPA | 16.11 | 800.231M |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About DC4.DE
Company Profile
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 11,000 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Company Info
IPO: 2005-04-14
DEXCOM INC
6340 Sequence Drive
San Diego CALIFORNIA US
Employees: 11050
Phone: 13026365400
DEXCOM INC / DC4.DE FAQ
What does DEXCOM INC do?
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 11,000 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
What is the current price of DC4 stock?
The current stock price of DC4.DE is 49.7 EUR. The price increased by 1.02% in the last trading session.
Does DC4 stock pay dividends?
DC4.DE does not pay a dividend.
What is the ChartMill rating of DEXCOM INC stock?
DC4.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
On which exchange is DC4.DE stock listed?
DC4.DE stock is listed on the Frankfurt Stock Exchange exchange.
Can you provide the PE ratio for DC4 stock?
The PE ratio for DEXCOM INC (DC4.DE) is 31.26. This is based on the reported non-GAAP earnings per share of 1.59 and the current share price of 49.7 EUR.
Can you provide the market cap for DEXCOM INC?
DEXCOM INC (DC4.DE) has a market capitalization of 19.13B EUR. This makes DC4.DE a Large Cap stock.